ATXS · As filed with the SEC
Astria Therapeutics balance sheet, by quarter
The statement as Astria Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Balance Sheets · USD
| USD | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|
| Statement | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | 96,280,000 | 76,319,000 | 54,385,000 | 59,820,000 | 80,899,000 | 87,212,000 | 172,012,000 | 175,530,000 |
| Short-term investments | 131,441,000 | 182,859,000 | 240,679,000 | 268,312,000 | 263,384,000 | 267,491,000 | 197,895,000 | 71,000,000 |
| Accounts receivable | 17,243,000 | — | — | — | — | — | — | — |
| Prepaid expenses and other current assets | 8,582,000 | 9,408,000 | 7,904,000 | 6,511,000 | 7,580,000 | 3,186,000 | 4,614,000 | 4,412,000 |
| Total current assets | 253,546,000 | 268,586,000 | 302,968,000 | 334,643,000 | 351,863,000 | 357,889,000 | 374,521,000 | 250,942,000 |
| Right-of-use asset | 4,254,000 | 4,546,000 | 4,833,000 | 5,114,000 | 5,390,000 | 5,715,000 | 210,000 | 363,000 |
| Other assets | 14,066,000 | 8,792,000 | 2,586,000 | 2,606,000 | 4,386,000 | 4,385,000 | 4,076,000 | 3,361,000 |
| Total assets | 271,866,000 | 281,924,000 | 310,387,000 | 342,363,000 | 361,639,000 | 367,989,000 | 378,807,000 | 254,666,000 |
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | 1,137,000 | 738,000 | 3,695,000 | 4,320,000 | 1,278,000 | 2,341,000 | 862,000 | 1,513,000 |
| Accrued expenses | 16,481,000 | 15,907,000 | 12,339,000 | 13,427,000 | 13,069,000 | 12,782,000 | 10,042,000 | 9,708,000 |
| Operating lease liabilities, current | 1,404,000 | 1,399,000 | 1,392,000 | 1,384,000 | 1,377,000 | 1,245,000 | 168,000 | 329,000 |
| Deferred revenue, current | 4,495,000 | — | — | — | — | — | — | — |
| Total current liabilities | 23,517,000 | 18,044,000 | 17,426,000 | 19,131,000 | 15,724,000 | 16,368,000 | 11,072,000 | 11,550,000 |
| Operating lease liabilities, net of current portion | 3,055,000 | 3,367,000 | 3,671,000 | 3,969,000 | 4,261,000 | 4,544,000 | — | — |
| Deferred revenue, net of current portion | 12,041,000 | — | — | — | — | — | — | — |
| Total liabilities | 38,613,000 | 21,411,000 | 21,097,000 | 23,100,000 | 19,985,000 | 20,912,000 | 11,072,000 | 11,550,000 |
| Stockholders' equity: | ||||||||
| Common stock, $0.001 par value per share, 150,000,000 shares authorized; 56,434,894 and 56,434,219 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 57,000 | 57,000 | 57,000 | 57,000 | 57,000 | 55,000 | 55,000 | 41,000 |
| Additional paid-in capital | 911,014,000 | 906,703,000 | 902,352,000 | 898,513,000 | 895,110,000 | 876,377,000 | 872,832,000 | 728,285,000 |
| Accumulated other comprehensive gain | 56,000 | (16,000) | 60,000 | 163,000 | 331,000 | (45,000) | (14,000) | — |
| Accumulated deficit | (773,198,000) | (741,555,000) | (708,503,000) | (674,794,000) | (649,168,000) | (624,634,000) | (600,462,000) | (580,534,000) |
| Total stockholders' equity | 233,253,000 | 260,513,000 | 289,290,000 | 319,263,000 | 341,654,000 | 347,077,000 | 367,735,000 | 243,116,000 |
| Total liabilities and stockholders' equity | 271,866,000 | 281,924,000 | 310,387,000 | 342,363,000 | 361,639,000 | 367,989,000 | 378,807,000 | 254,666,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.